To further confirm the role of IL‐33 in BTZ‐mediated anti‐MM activity in vivo, we constructed U226B1 cell xenograft mouse model to evaluate antitumor efficacy of IL‐33 and BTZ through mono‐ or combination therapies. The gene discussed is IL33; the disease is Miyoshi myopathy.